PRGO - Perrigo Company plc
| Previous Close | 54.53 |
| Open | 54.61 |
| Bid | 53.93 x 1100 |
| Ask | 53.94 x 800 |
| Day's Range | 53.79 - 54.67 |
| 52 Week Range | 36.28 - 58.02 |
| Volume | 541,548 |
| Avg. Volume | 1,053,365 |
| Market Cap | 7.3B |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | 29.85 |
| EPS (TTM) | 1.81 |
| Earnings Date | Feb 25, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | 0.84 (1.54%) |
| Ex-Dividend Date | 2019-11-27 |
| 1y Target Est | 52.60 |
- Insider Monkey
Is Perrigo Company (PRGO) Another High Profile Starboard Failed Bet?
Is Perrigo Company (NASDAQ:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
- Simply Wall St.
Here's What Perrigo Company plc's (NYSE:PRGO) P/E Is Telling Us
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...
- Zacks
Perrigo (PRGO) Up 4.1% Since Last Earnings Report: Can It Continue?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents
Edited Transcript of PRGO earnings conference call or presentation 6-Nov-19 1:00pm GMT
Q3 2019 Perrigo Company PLC Earnings Call
- Yahoo Finance
The stock market's biggest winners and losers of the past decade
With the 2010s officially drawing to a close, Yahoo Finance took a look at some of the biggest S&P 500 winners and losers of the past decade based on price returns.
- PR Newswire
Perrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth Strategy
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the branded over-the-counter (OTC) rights to Prevacid®24HR.
- Benzinga
Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling. Takeaways From ...
- PR Newswire
Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference
DUBLIN, Nov. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 10:00 AM EST on Wednesday, December 4, 2019. Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
- Benzinga
Witi, Perrigo Partner To Help Smokers Overcome Nicotine Addiction
Witi, a producer of medical-grade vaporization devices, announced Thursday it has partnered with Perrigo (NYSE: PRGO) to create a new smoking cessation product. The two companies plan to work on an electronic nicotine delivery system that would later be submitted for approval by the FDA and other international regulatory agencies. Perrigo is a dominant figure in nicotine replacement therapy, with a plethora of products intended to help smokers quit.
- Investor's Business Daily
Here's One Drugmaker That Popped On Earnings — And Two That Didn't
Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.
- GuruFocus.com
US Stocks Retreat Wednesday
CVS Health posts 3rd-quarter earnings beat Continue reading...
- Zacks
Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View
Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery. Stock down.
- Zacks
Perrigo (PRGO) Beats Q3 Earnings Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of 11.83% and -0.95%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Perrigo Company plc Reports Third Quarter 2019 Financial Results
Continues Successful Transformation to a Consumer Self-Care Company Raises 2019 Adjusted EPS Guidance DUBLIN , Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider ...
- GuruFocus.com
3 Loyal Dividend Payers Declare Distributions
Crawford & Company tops the list Continue reading...
- Simply Wall St.
Did You Manage To Avoid Perrigo's (NYSE:PRGO) Painful 65% Share Price Drop?
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
- PR Newswire
Perrigo Announces Quarterly Dividend
DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21 per share, payable on December 17, 2019 to shareholders of record on November 29, 2019. Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-Care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
- Zacks
What's in the Cards for Perrigo (PRGO) This Earnings Season?
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
- Zacks
Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
- Insider Monkey
Hedge Funds Are Betting On Perrigo Company plc (PRGO)
Is Perrigo Company plc (NYSE:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
- GuruFocus.com
Jerome Dodson to Speak at 2020 GuruFocus Value Conference
Founder and chairman of Parnassus Investments to make a speech at upcoming GuruFocus Value Conference Continue reading...
- Zacks
Medical Products Industry Outlook: Prospects Seem Promising
Medical Products Industry Outlook: Prospects Seem Promising
- PR Newswire
Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date
TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00 a.m. (EDT).
- Yahoo Finance
Perrigo Company Upgraded to Buy
This excerpt was brought to you by Argus Research using the Research Reports feature available through Yahoo Finance Premium. · Perrigo Company (PRGO), a longtime leader in OTC generics, had faced pressure over the past few years from industry-wide price erosion, challenges in its animal health business, and a reduction in FDA approvals. In addition, Perrigo sold its Animal Health business for $185 million.
